Polomar Health Shifts to Telehealth, Faces Losses Amidst Strategic Pivot

TL;DR

**PMHS is making a risky bet on telehealth and GLP-1s, but with significant losses and a low stock price, this S-1/A looks like a desperate attempt to raise capital, making it a speculative play at best.**

AI Summary

Polomar Health Services, Inc. (PMHS) filed an S-1/A on December 5, 2025, for the resale of 7,710,219 shares of common stock by selling stockholders at a fixed price of $0.20 per share, or prevailing market prices once listed on a national exchange. The company, operating Polomar Specialty Pharmacy, LLC, a Florida-licensed retail compounding pharmacy, has shifted its business model from local dermatological formulations to national online fulfillment of GLP-1 agonists and erectile dysfunction drugs. Polomar Pharmacy reported significant losses due to declining revenues and increased labor costs, stemming from this business model change and initial supply chain issues, despite resolving ingredient delays. The company secured a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. on September 26, 2025, for GLP-1 agonist prescriptions, with fulfillment commencing October 6, 2025, expecting steady revenue growth. PMHS also plans to launch SlimRx™ in early 2026 for weight loss medications and PoloMeds™ in Q1 2026 for diabetes and men's health compounds, aiming for 'wholesale' growth through third-party telehealth platforms like ForHumanity Health, Inc. and CareValidate.

Why It Matters

This S-1/A filing signals Polomar Health Services' strategic pivot from a local compounding pharmacy to a national telehealth-focused model, particularly in the high-growth GLP-1 agonist market. For investors, the resale of 7,710,219 shares at $0.20, significantly above the current $0.08 bid price, indicates potential dilution and a valuation disconnect, while the company's history of losses and dependence on third-party telehealth platforms introduce substantial risk. Employees face a changing operational landscape, and customers could benefit from increased access to specialized compounded medications, but the company's ability to scale and compete against larger, established telehealth providers and pharmaceutical companies remains a critical challenge.

Risk Assessment

Risk Level: high — The company explicitly states 'significant losses from operations' and 'insufficient access to capital to successfully implement its business plan.' Furthermore, the common stock is currently quoted on the OTCID Basic Market at a closing bid price of $0.08 on December 5, 2025, while selling stockholders may sell at a fixed price of $0.20 per share, indicating a substantial valuation gap and potential for significant dilution for new investors.

Analyst Insight

Investors should exercise extreme caution due to the high risk profile, including a history of losses and insufficient capital. Consider waiting for clear evidence of sustained revenue growth from the CareValidate agreement and successful launches of SlimRx and PoloMeds before considering an investment. The current $00.08 bid price versus the $0.20 offering price for selling stockholders suggests significant downside risk.

Key Numbers

• 7,710,219 — Shares of Common Stock (Number of shares offered for resale by selling stockholders)
• $0.20 — Fixed Price Per Share (Price at which selling stockholders may sell shares until listed on an exchange)
• $0.08 — Last Reported Closing Bid Price (PMHS common stock price on OTCID Basic Market as of December 5, 2025)
• 30 — States Licensed (Number of states Polomar Pharmacy is currently licensed to deliver compounded medications)
• 2026 — Launch Year (Expected launch year for SlimRx™ platform)
• Q1 2026 — Launch Quarter (Expected launch quarter for PoloMeds™ platform)
• September 26, 2025 — Agreement Date (Date of pharmacy services agreement with CareValidate, Inc.)
• October 6, 2025 — Fulfillment Start Date (Date Polomar began fulfilling prescriptions for CareValidate)
• $350,000 — Consideration for CWR Transaction (Aggregate consideration paid by CWR 1, LLC for Transferred Shares)
• 50,000,000 — Shares Returned for Cancellation (Common Stock shares returned by CWR 1, LLC on October 9, 2024)

Key Players & Entities

• Polomar Health Services, Inc. (company) — Registrant and issuer of common stock
• Polomar Specialty Pharmacy, LLC (company) — Florida-licensed retail compounding pharmacy, wholly owned subsidiary
• CareValidate, Inc. (company) — Third-party telehealth platform partner for GLP-1 agonist prescriptions
• ForHumanity Health, Inc. (company) — Third-party telehealth platform partner for inhalable sildenafil
• Terrence M. Tierney (person) — President of Polomar Health Services, Inc.
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• CWR 1, LLC (company) — Purchaser of 83% of common stock and 100% of Series A Preferred Stock in CWR Transaction
• Fastbase, Inc. (company) — Former record and beneficial owner of Polomar Health Services, Inc. shares
• Stephen E. Fox, Esq. (person) — Legal counsel from Ruskin Moscou Faltischek, P.C.
• Samantha M. Guido, Esq. (person) — Legal counsel from Ruskin Moscou Faltischek, P.C.

FAQ

Risk Factors

• Significant Operating Losses [high — financial]: The company has experienced significant losses due to declining revenues and increased labor costs. This is attributed to the business model shift and initial supply chain issues, despite resolving ingredient delays. The company's ability to achieve profitability is dependent on the success of its new product launches and partnerships.
• Reliance on Third-Party Platforms [medium — operational]: The company plans to achieve 'wholesale' growth through third-party telehealth platforms like ForHumanity Health, Inc. and CareValidate, Inc. This reliance introduces risks related to the performance, stability, and contractual terms of these partnerships.
• Pharmacy Licensing and Compliance [medium — regulatory]: Polomar Pharmacy operates as a compounding pharmacy and is licensed in 30 states. Expansion into national online fulfillment requires adherence to varying state and federal regulations for prescription drugs, compounding, and telehealth, posing compliance challenges.
• Competition in GLP-1 and ED Markets [medium — market]: The company is entering competitive markets for GLP-1 agonists and erectile dysfunction drugs. The success of SlimRx™ and PoloMeds™ will depend on their ability to differentiate and compete effectively against established players and emerging treatments.
• Dependence on New Product Launches [high — financial]: The company's future revenue growth is heavily dependent on the successful launch and market adoption of SlimRx™ in early 2026 and PoloMeds™ in Q1 2026. Any delays or failures in these launches could significantly impact financial performance.

Industry Context

The pharmaceutical and healthcare services industry is highly competitive and subject to extensive regulation. The compounding pharmacy sector, in particular, faces scrutiny regarding quality control and compliance. The rise of telehealth and direct-to-consumer models is transforming how patients access medications, creating opportunities for specialized pharmacies like Polomar, but also increasing competition.

Regulatory Implications

Polomar operates in a heavily regulated environment, requiring compliance with state and federal laws governing pharmacy practice, compounding, and prescription drug distribution. The shift to national online fulfillment necessitates adherence to diverse state licensing requirements and DEA regulations, increasing compliance burdens and potential for penalties.

What Investors Should Do

1. Monitor new product launch performance
2. Assess partnership stability and expansion
3. Evaluate regulatory compliance and licensing
4. Analyze financial performance post-listing

Key Dates

• 2024-10-09: CWR 1, LLC returned 50,000,000 shares for cancellation — This action reduced the number of outstanding shares, potentially impacting per-share metrics if not accompanied by a proportional decrease in liabilities or increase in assets.
• 2025-09-26: Pharmacy services agreement with CareValidate, Inc. signed — This agreement is crucial for the company's new business model, securing a partner for fulfilling GLP-1 agonist prescriptions and providing a pathway for revenue generation.
• 2025-10-06: Fulfillment for CareValidate, Inc. commenced — Marks the operational start of the new business model, initiating revenue generation from the CareValidate partnership.
• 2025-12-05: S-1/A filing for resale of 7,710,219 shares — This filing indicates the company's intent to allow existing shareholders to sell their shares, potentially increasing liquidity but also signaling a bearish sentiment due to the fixed low price and current OTC trading.
• 2026-01-01: Expected launch of SlimRx™ platform — Represents a key expansion into the weight loss medication market, a significant growth opportunity for the company.
• 2026-01-01: Expected launch of PoloMeds™ platform (Q1 2026) — This launch targets the diabetes and men's health compound markets, further diversifying the company's product offerings and revenue streams.

Glossary

S-1/A

An amended registration statement filed with the U.S. Securities and Exchange Commission (SEC) for the resale of securities. (This is the document through which Polomar Health Services is registering shares for resale by existing stockholders.)

Selling Stockholders

Existing shareholders who are offering to sell their shares of a company's stock. (These are the parties selling the 7,710,219 shares of Polomar Health Services common stock in this offering.)

Compounding Pharmacy

A pharmacy that prepares customized medications for individual patients based on a prescription from a licensed healthcare practitioner. (Polomar operates as a compounding pharmacy, which has specific regulatory requirements and operational complexities.)

GLP-1 agonists

A class of drugs that mimic the effects of glucagon-like peptide-1, often used for managing type 2 diabetes and weight loss. (These are a key focus for Polomar's new business model, indicating a strategic move into a high-demand therapeutic area.)

Telehealth platforms

Platforms that provide healthcare services remotely using telecommunications technology. (Polomar intends to leverage these platforms to reach a national customer base for its specialized pharmacy services.)

OTCID Basic Market

A quotation service for over-the-counter (OTC) securities that are not listed on major national exchanges. (Indicates that Polomar's stock is currently trading on a less regulated and typically less liquid market, with a low bid price of $0.08.)

Year-Over-Year Comparison

This S-1/A filing represents a significant pivot from previous operations, focusing on a national online fulfillment model for specialized medications rather than local dermatological formulations. While specific comparative financial data from a prior S-1 filing is not detailed here, the current filing highlights a business model shift that has led to 'significant losses due to declining revenues and increased labor costs.' The company is now seeking to generate steady revenue growth through new partnerships and product launches, indicating a strategic attempt to recover from past financial performance.

Key Financial Figures

• $0.001 — 0,219 shares of common stock, par value $0.001 per share ("Common Stock"), of Polomar
• $0.20 — ll the Common Stock at a fixed price of $0.20 per share until the shares of Common St
• $0.08 — sing bid price for our Common Stock was $0.08. You should read this prospectus and
• $350,000 — ("CWR") for aggregate consideration of $350,000 (collectively referred to as the "CWR T
• $700,000 — greed to loan to Polomar Pharmacy up to $700,000 in one or more advances from time to ti
• $522,788 — under the Reprise Note in the amount of $522,788 was made, which funds were used to repa
• $808,875.30 — rincipal amount of the Reprise Note was $808,875.30 plus accrued interest of $88,674.44. Al
• $88,674.44 — as $808,875.30 plus accrued interest of $88,674.44. Also, on June 30, 2025, Reprise exchan
• $300,000 — so, on June 30, 2025, Reprise exchanged $300,000 of the amount due and owing under the R
• $597,549.74 — that the remaining principal balance of $597,549.74 of the Reprise Note shall be subject to
• $250,000 — CWR agreed to loan to the Company up to $250,000 in one or more advances from time to ti
• $157,622.56 — raw under the CWR Note in the amount of $157,622.56 was made, which funds are being used to
• $450,000 — ng principal amount of the CWR Note was $450,000, inclusive of all accrued interest. On
• $150,000 — ial terms: The Company may draw up to $150,000 per the terms of the CWR Note II. The C
• $248,000 — rms of the CWR Note II in the amount of $248,000 plus accrued interest of $509.59. An in

Filing Documents

• forms-1a.htm (S-1/A) — 3222KB
• ex5-1.htm (EX-5.1) — 13KB
• ex10-15.htm (EX-10.15) — 18KB
• ex10-16.htm (EX-10.16) — 26KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107.htm (EX-FILING FEES) — 44KB
• form10-k_001.jpg (GRAPHIC) — 6KB
• form10-k_002.jpg (GRAPHIC) — 4KB
• fin_001.jpg (GRAPHIC) — 3KB
• ex23-1_001.jpg (GRAPHIC) — 3KB
• ex23-1_002.jpg (GRAPHIC) — 3KB
• ex23-2_001.jpg (GRAPHIC) — 22KB
• ex5-1_001.jpg (GRAPHIC) — 12KB
• 0001493152-25-026439.txt ( ) — 11680KB
• pmhs-20250930.xsd (EX-101.SCH) — 56KB
• pmhs-20250930_cal.xml (EX-101.CAL) — 71KB
• pmhs-20250930_def.xml (EX-101.DEF) — 498KB
• pmhs-20250930_lab.xml (EX-101.LAB) — 468KB
• pmhs-20250930_pre.xml (EX-101.PRE) — 489KB
• forms-1a_htm.xml (XML) — 1664KB
• ex107_htm.xml (XML) — 9KB

Risk Factors

Risk Factors 10 Unaudited Pro Forma Combined Financial Information 18

Use of Proceeds

Use of Proceeds 29 Selling Stockholders 30 Plan of Distribution 31

Description of Securities

Description of Securities 32 Market Price of and Dividends on Common Stock and Related Stockholder Matters 35

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 36

Legal Proceedings

Legal Proceedings 50 Board of Directors and Management 50

Executive Compensation

Executive Compensation 54

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 61 Certain Relationships and Related Transactions 62 Legal Matters 63 Experts 63 Where You Can Find More Information 63

Financial Statements

Financial Statements F-1 i ABOUT THIS PROSPECTUS Unless the context otherwise requires or indicates, all references to "we", "us", "our", "ourselves", "the Company," and "Polomar" refer to Polomar Health Services, Inc. a Nevada corporation, (formerly known as Trustfeed Corp. and prior to that, Healthmed Services Ltd. and Telemax Communications) and, as the context may require, its consolidated subsidiaries. References to our "Common Stock" refer to the common stock, par value $0.001 per share, of Polomar. You should rely only on the information contained in this prospectus. Neither we nor any of the Selling Stockholders have authorized any other person to provide you with different or additional information. Neither we nor any of the Selling Stockholders take responsibility for, nor can we provide assurance as to the reliability of, any other information that others may provide. The information contained in this prospectus is accurate only as of the date of this prospectus or such other date stated in this prospectus, and our business, financial condition, results of operations and/or prospects may have changed since those dates. This prospectus contains summaries of certain provisions contained in some of the documents described in this prospectus, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to in this prospectus have been filed, will be filed, or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, any you may obtain copies of those documents as described under " Where You Can Find More Information ." Neither we nor any of the Selling Stockholders are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Except as otherwise set forth in this prospectus, neither we nor any of the Selling Stockholders hav

View Full Filing

View this S-1/A filing on SEC EDGAR